Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
Status:
Completed
Trial end date:
2012-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three
times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central
nervous system (CNS) iron deposition, and d) immune status in subjects with
relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques.